Application of Magnesium-rich Artificial Cerebrospinal Fluid in Aneurysmal Subarachnoid Hemorrhage

Effects of Magnesium-rich Artificial Cerebrospinal Fluid on the Incidence of Cerebral Vasospasm and Clinical Prognosis of Patients With Aneurysmal Subarachnoid Hemorrhage

Aneurysmal subarachnoid hemorrhage (aSAH) is a common type of acute hemorrhagic stroke. One of its complications, cerebral vasospasm (CVS), is the main cause of death and disability, with an incidence of up to 30%-90%. Blood and its metabolites are vital reasons for CVS. Normal saline, as an intraoperative irrigation fluid for the surgery of aneurysm clipping, can induce secondary damage to the brain. In this study, a new type of magnesium-rich artificial cerebrospinal fluid (MACSF) has been designed, which has similar ionic concentration, pH value and osmotic pressure compared with the physiological cerebrospinal fluid. It has been confirmed by animal experiments that MACSF can relieve the hyper-responsiveness of cerebral arteries to ET and 5-HT induced by hemorrhagic CSF from patients with aSAH by down-regulating the expression of ETA, contractile ETB and 5-HT1B receptors in the previous research. Therefore, MACSF may have potential effects on preventing and treating CVS. In this study, we plan to apply MACSF as an intraoperative irrigation fluid for the surgery of aneurysm clipping (MACSF group), which is compared with normal saline (historical control group). To evaluate the effects of MACSF on reducing the incidence of CVS and improving the clinical prognosis of patients with aSAH, the occurrence of CVS within 14 days after aneurysm clipping, NIHSS score, as well as mRS scores at 1, 3 and 6 months after aSAH will be recorded and compared. CVS related biomarkers will be used to evaluate the relationship between the occurrence of CVS and the levels of biomarkers in both CSF and blood samples from MACSF group.

Study Overview

• Status: Recruiting
• Conditions: Aneurysmal Subarachnoid Hemorrhage
• Intervention / Treatment: Other: Magnesium-Rich Artificial Cerebrospinal Fluid

Detailed Description

From now on, participants who meet the inclusion and exclusion criteria in our hospital will be recruited in the intervention group, if they and their relatives are willing to join in the study. For the historical control group, in which patients were treated by aneurysm clipping in Department of Neurosurgery of the First Affiliated Hospital of Xi'an Jiaotong University during the previous nine months, normal saline (0.9% Sodium Chloride Injection) was applied as intraoperative perfusion solution for their operation. For the intervention group, MACSF will be used. (The composition and concentration of MACSF is as follows: Na+: 146.2 mEq/l, K+: 2.7 mEq/l, Mg2+: 4.2 mEq/l, Cl-: 123 mEq/l, HCO3-: 23.2 mEq/l, Glucose: 0.75 g/l. MACSF is prepared by the staff of Pharmacy Intravenous Admixture Services of First Affiliated Hospital of Xi'an Jiaotong University, according to a specific formula in the specific working area. The whole procedure follow the aseptic principles strictly. Fresh-made MACSF will be placed in a specific container and send to the operating room through specific channels.) Then, for the patients who have signed the informed consent, blood (6ml) and CSF (3ml) samples will be collected during and every other day after the surgery for 14 days. The blood samples should be drawn into a non-anticoagulant tube and a heparin anticoagulant tube respectively. All the samples will be transferred to BioBank of the First Affiliated Hospital of Xi'an Jiaotong University in a liquid nitrogen tank. After re-melted in a water bath of 37℃, the CSF and blood samples will be centrifuged at 4℃ for 10min at 2000r/min, and then the supernatant will be collected and stored at -80℃. At the end of this study, the contents of NPY，MMP-9，MIF，TNF-α，Mg2+ and Ca2+in the samples will be detected by ELISA or mass spectrometry. Transcranial Doppler (TCD) will be observed within 14 days after the operation (daily for the first three days and every other day for the following days). CVS will be diagnosed by TCD, the diagnostic criteria will be described later. CT scan of the brain should be done at least once a week and rechecked anytime when necessary. If there is new low-density lesions, delayed cerebral infarction (DCI) will be diagnosed. The prognosis will be assessed at 1, 3 and 6 months after aSAH onset according to modified Rankin Scale (mRS) . Meanwhile, some indicators will be used to evaluate the safety of MACSF application, which incluiding secondary infection, fluctuation of intracranial pressure and hypermagnesemia. The diagnostic criteria and the solutions will be described in the next part.

• Study Type: Interventional
• Enrollment (Anticipated): 70
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Han Xiangning; Phone Number: 0086-18392002455; Email: hxiangning@163.com
• Study Contact Backup: Name: Luo Guogang, doctor; Phone Number: 0086-13991974085; Email: lguogang@163.com

Study Locations

• China
  • Xi'an, China, 710061
    • Recruiting
    • The First Affiliated Hospital of Xi'an Jiaotong University
    • Contact: Guogang Luo, Ph.D.; Phone Number: 86-13991974085

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 80 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Patient is between 18 and 80 years of old;
• aSAH is diagnosed by CTA, DSA or other cranial imaging examination;
• Patient is admitted to hospital within 72 hours after aSAH onset;
• Aneurysm is clipped within 36 hours after admission;
• Patient and his/her relatives are informed and agree to accept the above treatment plan.

Exclusion Criteria:

• Cause of the SAH is not rupture of an intracranial aneurysm;
• Time from SAH onset to admission is longer than 72 hours;
• Time from admission to surgery is longer than 36 hours;
• The patient dose not choose clipping;
• Patient has other serious diseases, such as heart failure, kidney failure, liver failure, etc;
• Patient or his/her relatives refuse to accept the above research plan.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Non-Randomized
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
No Intervention: Historical control group; The patients were treated by aneurysm clipping in our hospital in the previous nine months, and normal saline (0.9% Sodium Chloride Injection) had applied as intraoperative perfusion solution in operation of the historical control group. All of the 35 patients selected should meet the inclusion and exclusion criteria of this study.
Experimental: MACSF group; Use Magnesium-Rich Artificial Cerebrospinal Fluid (MACSF) in the operation, and the remaining treatments should strictly follow the guidelines as same as the historical control group.	Other: Magnesium-Rich Artificial Cerebrospinal Fluid; The Magnesium-Rich Artificial Cerebrospinal Fluid (MACSF) is composed of several qualified clinical intravenous injections according to a specific formula, which has similar physical and chemical properties to physiological CSF. MACSF will be freshly made and used. It will be prepared by trained professionals on a specific workbench and sent to the operating room in a special container. Finally, it will be used in the operation by the neurosurgeons. Aseptic principles should be enforced strictly during the whole procedures, including preparation, transportation and application.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Incidence and severity of CVS during and after operation	Transcranial Doppler (TCD) will be used to evaluate the occurrence and severity of CVS, which will be diagnosed according to the following criteria for TCD. First, the mean blood flow velocity of tested arteries is higher than 120cm/s. Second, the mean blood flow velocity of tested arteries increases more than 15cm/s or 20% compared with the previous time. Third, the Lindeggard Index (mean blood flow velocity of MCA/mean blood flow velocity of ipsilateral eICA) is higher than 3	Within 14 days after surgery
mRS (modified Rankin Scale）	Assess patients' prognosis by the score of modified Rankin Scale.In the mRS, the lowest score is 0, and the highest score is 5. A score of 0 indicates the patients have no symptoms at all, and a score of 5 indicates the patients have severe disability, bed rest, incontinence, and need for continuous care and attention. In this study, we evaluate patient's outcomes by the following criteria. Favorable outcome was defined as mRS<3, whereas poor outcome was mRS≥3.	Day 30
mRS (modified Rankin Scale）	Assess patients' prognosis by the score of modified Rankin Scale.In the mRS, the lowest score is 0, and the highest score is 5. A score of 0 indicates the patients have no symptoms at all, and a score of 5 indicates the patients have severe disability, bed rest, incontinence, and need for continuous care and attention. In this study, we evaluate patient's outcomes by the following criteria. Favorable outcome was defined as mRS<3, whereas poor outcome was mRS≥3.	Day 60
mRS (modified Rankin Scale）	Assess patients' prognosis by the score of modified Rankin Scale.In the mRS, the lowest score is 0, and the highest score is 5. A score of 0 indicates the patients have no symptoms at all, and a score of 5 indicates the patients have severe disability, bed rest, incontinence, and need for continuous care and attention. In this study, we evaluate patient's outcomes by the following criteria. Favorable outcome was defined as mRS<3, whereas poor outcome was mRS≥3.	Day 90

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Levels of biomarkers in cerebrospinal fluid (CSF)	Cerebrospinal fluid samples were collected during and every other day after surgery for 14 days to evaluated the effect of MACSF on Neuropeptide Y (NPY, ng/L), Matrix Metalloproteinase-9(MMP-9, ng/L), Macrophage Migration Inhibitory Factor (MIF, ng/L), Tumor Necrosis Factor-α(TNF-α, ng/L).	Within 14 days after surgery
Levels of ion concentration in cerebrospinal fluid (CSF)	Cerebrospinal fluid samples were collected during and every other day after surgery for 14 days to evaluated the effect of MACSF on Mg2+ (mEq/L)and Ca2+ (mEq/L).	Within 14 days after surgery
Levels of biomarkers in blood	Blood samples were collected during and every other day after surgery for 14 days to evaluated the effect of MACSF on Neuropeptide Y (NPY, ng/L), Matrix Metalloproteinase-9(MMP-9, ng/L), Macrophage Migration Inhibitory Factor (MIF, ng/L), Tumor Necrosis Factor-α(TNF-α, ng/L).	Within 14 days after surgery
Levels of ion concentration in blood	Blood samples were collected during and every other day after surgery for 14 days to evaluated the effect of MACSF on Mg2+ (mEq/L)and Ca2+ (mEq/L).	Within 14 days after surgery
Duration of hospitalization	Length of hospital stay in the intensive care unit, total length of hospital stay, the days of anti-CVS drugs use, etc	up to 60 days

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
Incidence and severity of MACSF-induced infection	If the patient has some symptoms of infection, the doctor in charge must determine whether it is MACSF-induced infection and assess the severity. First, the MACSF-induced infection will be diagnosed by the patient's symptoms and the MACSF sample's pathogenic detection. Second, the severity of infection will be evaluated by the indicators including the duration of fever, the kinds of antibiotics, the duration of antibiotics use and the results of CSF examination	up to 14 days
Fluctuation of intracranial pressure（ICP）	ICP will be assessed by invasive ICP monitoring and lumbar puncture. The severity will be evaluated by days of use of dehydrated drugs	up to 14 days
Incidence of hypermagnesemia	Pay close attention to the clinical manifestations of fatigue, disappearance of tendon reflex and decreased blood pressure, and monitor the blood electrolyte level dynamically to assess the incidence of hypermagnesemia	up to 14 days

Collaborators and Investigators

• Sponsor: First Affiliated Hospital Xi'an Jiaotong University
• Investigators: Principal Investigator: Luo Guogang, MD,PHD, First Affiliated Hospital Xi'an Jiaotong University

Study record dates

Study Major Dates

• Study Start (Actual): March 1, 2020
• Primary Completion (Anticipated): July 30, 2022
• Study Completion (Anticipated): July 30, 2022

Study Registration Dates

• First Submitted: March 16, 2020
• First Submitted That Met QC Criteria: April 20, 2020
• First Posted (Actual): April 24, 2020

Study Record Updates

• Last Update Posted (Actual): May 10, 2022
• Last Update Submitted That Met QC Criteria: May 6, 2022
• Last Verified: March 1, 2022

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Pathologic Processes; Cardiovascular Diseases; Vascular Diseases; Cerebrovascular Disorders; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Intracranial Hemorrhages; Hemorrhage; Subarachnoid Hemorrhage
• Other Study ID Numbers: XJYFY-2019N28

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: Yes

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No